leisure time -WSS

leisure time

author：focus 2025-09-07 04:04:46 - browse：5198

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Surge of respiratory disease in China has likely explanation

WSS

SNAP should offer more nutrition education

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Hospitals look to new technology to keep health care workers safe

Congress must reauthorize a committee to support older Americans

Medicare drug price negotiation hasn't dried up venture capital

Why medical students are struggling with mental health

hotspot

leisure time

knowledge

Sports medicine is finally prioritizing gender equality

In Spain, a hospital brews its own CAR

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Hospitals owned by private equity see complications spike 25%

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Psychedelics group wrestles with new pharma identity

Keeping primary care docs in field isn't impossible, says AAFP CEO

What does generative AI mean for health care? We asked experts

What STAT readers think about the FDA and patient advocacy

knowledge

David Sabatini, ex

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Anthos stroke drug appears safer than common blood thinner

Virtual care provider acquires bankrupt Pear's prescription apps

What STAT readers think about the FDA and patient advocacy

Bristol Myers buys into radiopharmaceuticals with RayzeBio

explore

leisure time

focus

leisure time